Joint marketing efforts are being set up after Xendo transferred all its bioprocessing activities to Batavia Bioservices. Collectively the Netherlands-based companies have the scale to handle larger projects and this was a motivating factor in the deal.
Menzo Havenga, CEO of Batavia Bioservices, said: “Xendo BV and Batavia Bioservices BV together have more critical mass and therefore are able to execute larger, more complex customer programmes.”
Activities at the Xendo unit include upstream and downstream bioprocessing, single use fermentation systems, and continuous chromatography using SMB technology. Batavia Bioservices highlighted the microbial process understanding it will gain through the collaboration.
Transferring assets to Batavia Bioservices allows Xendofocus on its other operations. In the collaboration Batavia Bioservices will offer process development and analytical services and Xendo will handle engineering, regulatory and clinical support.
André van de Sande, CEO of Xendo BV, said: “By combining our forces both companies are better positioned to service our customers. This helps Xendo BV, both in the Netherlands and international, to further expand.” Sande was appointed CEO in February.
Batavia Bioservices expansion
In January Batavia Bioservices set up a US subsidiary. Montgomery County, Maryland was chosen as the office location because of the concentration of biotechs, presence of the US National Institutes of Health and academic activity.
Entry into the US was accompanied by expansion of a site in The Netherlands. Laboratory and office space was added to support an expansion of upstream and downstream process development work.